Article
Loss of Tuberous Sclerosis Complex 2 (TSC2) Is Frequent in Hepatocellular Carcinoma and Predicts Response to mTORC1 Inhibitor Everolimus.
Molecular cancer therapeutics - 1 May 2015
Huynh Hung, Hao Huai-Xiang, Chan Stephen L, Chen David, Ong Richard, Soo Khee Chee, Pochanard Panisa, Yang David, Ruddy David, Liu Manway, Derti Adnan, Balak Marissa N, Palmer Michael R, Wang Yan, Lee Benjamin H, Sellami Dalila, Zhu Andrew X, Schlegel Robert, Huang Alan
Abstract excerpt
Hepatocellular carcinoma (HCC) is the third leading cause of cancer deaths worldwide and hyperactivation of mTOR signaling plays a pivotal role in HCC tumorigenesis. Tuberous sclerosis complex (TSC), a heterodimer of TSC1 and TSC2, functions as a negative regulator of mTOR signaling. In the current study, we discovered that TSC2 loss-of-function is common in HCC. TSC2 loss was found in 4 of 8 HCC cell lines and 8...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.